<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    OncoSec Medical Incorporated

    OncoSec Medical Incorporated

    OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...

    OncoSec Medical Incorporated is a clinical-stag...

    Filing Type:    PU
    Chembio Diagnostics, Inc.

    Chembio Diagnostics, Inc.

    Chembio is a leading point-of-care diagnostics company focused on detecting and di...

    Chembio is a leading point-of-care diagnostics ...

    Filing Type:    PU
    Menlo Therapeutics Inc.

    Menlo Therapeutics Inc.

    We are a late stage biopharmaceutical company focused on the development and comme...

    We are a late stage biopharmaceutical company f...

    Filing Type:    PU
    Bellerophon Therapeutics, Inc.

    Bellerophon Therapeutics, Inc.

    At Bellerophon Therapeutics, we aim to transform the lives of people suffering fro...

    At Bellerophon Therapeutics, we aim to transfor...

    Filing Type:    PU
    CohBar, Inc.

    CohBar, Inc.

    CohBar, Inc. is a leader in the research and development of mitochondria based the...

    CohBar, Inc. is a leader in the research and de...

    Filing Type:    PU
    Hepion Pharmaceuticals, Inc.

    Hepion Pharmaceuticals, Inc.

    Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical compan...

    Hepion Pharmaceuticals (Nasdaq: HEPA) is a clin...

    Filing Type:    PU
    argenx SE

    argenx SE

    argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...

    argenx is a clinical-stage biotechnology compan...

    Filing Type:    PU
    UroGen Pharma Ltd.

    UroGen Pharma Ltd.

    UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanc...

    UroGen Pharma Ltd. is a clinical-stage biopharm...

    Filing Type:    PU
    Intellia Therapeutics, Inc.

    Intellia Therapeutics, Inc.

    Intellia Therapeutics is a leading genome editing company focused on developing cu...

    Intellia Therapeutics is a leading genome editi...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.